TOKYO -- Japan's health ministry is working to approve at-home use of the COVID-19 antibody cocktail available to inpatients, as the country's surge in new cases forces many hospitals to reserve beds only for the sickest.
The treatment, developed by U.S.-based Regeneron Pharmaceuticals, is believed to reduce the risk of severe symptoms and death by 70%. The medication is geared toward patients with mild to moderate symptoms, and it is largely administered via IV drip to high-risk groups like the elderly and those with preexisting conditions.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
